Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?
Chemotherapy-induced cardiotoxicity, is a well-known and potentially serious complication strongly impacting the quality of life and overall survival of breast cancer patients. The current diagnostic approach to detect cardiac damage is the estimation of left ventricular ejection fraction by echocardiography. However, this approach exhibits less sensitivity toward early prediction of cardiomyopathy, not allowing for preventive strategies. Measurement of serum cardiac-specific biomarkers can be a valid diagnostic tool for identifying patients prone to developing cardiotoxocity and in whom closer cardiac monitoring and preventive strategies are pivotal. In this article, we review work done on biomarkers in recent years, with an emphasis on troponin and B-type natriuretic peptide, which are currently the most studied in this field. We also briefly discuss current and emerging imaging techniques for early detection of cardiomyopathy.
Published In/Presented At
Chaudry, M., Banchs, J., & Chavez-MacGregor, M. (2016). Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. Biomarkers in medicine, 10(3), 315–328. https://doi.org/10.2217/bmm.15.124
Medicine and Health Sciences
Department of Medicine